LDS/Medical Tests/MYOZ2 (Calsarcin-1) Gene Mutation Analysis

MYOZ2 (Calsarcin-1) Gene Mutation Analysis

The MYOZ2 gene that is located in the long (q) arm of chromosome 4 at position 26 encodes for the Calsarcin-1 muscle protein. The Calsarcin-1 isoform is expressed in cardiac muscle and slow-twitch skeletal muscle. It serves as an intracellular binding protein to tether calcineurin to alpha-actinin, gamma-filamin, TCAP/telethonin and LDB3/ZASP at Z-discs. It plays an important role in the modulation of calcineurin signaling and inhibits a pathological cardiac hypertrophic response.

Mutations in this gene cause familial hypertrophic cardiomyopathy type 16, a hereditary heart disorder. Familial hypertrophic cardiomyopathy (FHCM) is typically inherited as an autosomal dominant disease characterized by left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels.

The majority of FHCM patients are asymptomatic. Only about 25% develop symptom such as dyspnea, syncope, collapse, palpitations, and chest pain. The disorder has inter- and intra-familial variability ranging from benign to malignant forms that have a high risk of cardiac failure and sudden cardiac death. FHCM is the most common cause of sudden cardiac death in young people with an estimated prevalence of 1:500 in the general adult population. The majority of the mutations in HCM are missense, insertion/deletion and frame-shift mutations. Mutations in MYOZ2 account for less than 1% of FHCM cases.

  • Aids in the diagnosis of familial hypertrophic cardiomyopathy
  • Carrier screening for relatives and those with the family history
  • Prenatal carrier screening for those with the family history
Mutation or pathogenic variants in MYOZ2 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Targeted sequence analysis by next generation sequencing (NGS), deletions or duplications detection by PCR or multiplex ligation-dependent probe amplification (MLPA) analysis.

Whole blood (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Creatine phosphokinase, Creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), troponin T, myosin light chain-1 (MLC-1), electrocardiogram, chest X-ray, exercise stress echocardiography, cardiac catheterization and magnetic resonance imaging (MRI).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login